全文获取类型
收费全文 | 1248篇 |
免费 | 78篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 72篇 |
妇产科学 | 13篇 |
基础医学 | 126篇 |
口腔科学 | 45篇 |
临床医学 | 127篇 |
内科学 | 304篇 |
皮肤病学 | 23篇 |
神经病学 | 27篇 |
特种医学 | 244篇 |
外科学 | 86篇 |
综合类 | 61篇 |
预防医学 | 66篇 |
眼科学 | 21篇 |
药学 | 50篇 |
中国医学 | 9篇 |
肿瘤学 | 49篇 |
出版年
2024年 | 2篇 |
2022年 | 6篇 |
2021年 | 11篇 |
2020年 | 8篇 |
2019年 | 14篇 |
2018年 | 18篇 |
2017年 | 11篇 |
2016年 | 8篇 |
2015年 | 28篇 |
2014年 | 47篇 |
2013年 | 66篇 |
2012年 | 38篇 |
2011年 | 44篇 |
2010年 | 44篇 |
2009年 | 67篇 |
2008年 | 35篇 |
2007年 | 54篇 |
2006年 | 35篇 |
2005年 | 35篇 |
2004年 | 35篇 |
2003年 | 22篇 |
2002年 | 26篇 |
2001年 | 19篇 |
2000年 | 17篇 |
1999年 | 17篇 |
1998年 | 79篇 |
1997年 | 55篇 |
1996年 | 66篇 |
1995年 | 44篇 |
1994年 | 50篇 |
1993年 | 44篇 |
1992年 | 10篇 |
1991年 | 6篇 |
1990年 | 11篇 |
1989年 | 39篇 |
1988年 | 27篇 |
1987年 | 25篇 |
1986年 | 19篇 |
1985年 | 13篇 |
1984年 | 16篇 |
1983年 | 15篇 |
1982年 | 14篇 |
1981年 | 20篇 |
1980年 | 13篇 |
1979年 | 14篇 |
1978年 | 9篇 |
1977年 | 16篇 |
1976年 | 8篇 |
1975年 | 11篇 |
1973年 | 2篇 |
排序方式: 共有1335条查询结果,搜索用时 31 毫秒
151.
中西医结合治疗老年高脂血症 总被引:2,自引:1,他引:2
目的:探讨中西医结合治疗高脂血症的临床疗效。方法:符合高脂血症标准的老年患者120例,随机分为A、B2组各60例,A组采用益肾化淤、利湿化浊为主的中药及西药辛伐他汀片治疗;B组则单纯用辛伐他汀片治疗。治疗前及治疗4周后2组均行全套血脂水平测定。结果:与B组比较,A组血清总胆固醇(TC)及甘油三酯(TG)均明显下降,HDL明显上升(均P〈0.05);A组临床控制率明显高于B组(P〈0.05);治疗后A组患者未见肝功能损害,B组转氨酶及转肽酶轻度异常,2例。停药3个月后,A组复发率低于B组(2.2%、8.8%,P〈0.05)。结论:中西医结合治疗老年高脂血症的临床效果明显优于单一的一种治疗方法,值得临床进一步推广应用。 相似文献
152.
Although the intercellular adhesion molecule-1 (ICAM-1) is constitutively expressed at a low level on a subpopulation of hematopoietic cells, on vascular endothelium, on fibroblasts, and on certain epithelial cells, it is dramatically increased at sites of inflammation. Interferon-gamma (IFN-gamma) and phorbol myristate acetate (PMA) are known to increase the expression of ICAM-1 on many cell types. Because both human and murine ICAM-1 mRNAs contain putative destabilizing AUUUA sequences in their 3' untranslated regions (UTRs), we examined the role of mRNA stability in the regulation of ICAM-1 gene expression. The treatment of the murine monocytic cell line P388D1, which constitutively expresses ICAM-1 mRNA at a low level, with IFN- gamma or PMA rapidly enhanced the level of ICAM-1 mRNA and dramatically prolonged its half-life. To determine whether the putative destabilizing sequences are responsible for this effect of IFN-gamma and PMA, fibroblast L cells were transfected with either the full- length ICAM-1 cDNA or a truncated form (ICAM-1 delta 3) lacking the putative destabilizing AUUUA sequences. Although ICAM-1 delta 3 mRNA was more stable than the full-length ICAM-1 mRNA, IFN-gamma treatment induced the accumulation of both mRNA species and prolongation of their half-lives. The transplantation of the ICAM-1 delta 3' UTR into a stable ICAM-2 mRNA rendered it unstable, and it was unresponsive to IFN- gamma. Therefore, the treatment with IFN-gamma stabilizes the otherwise labile ICAM-1 mRNA, but the IFN-gamma-responsive sequence may at least in part reside within the protein coding region. PMA also upregulated ICAM-1 gene expression by mRNA stabilization. However, unlike IFN- gamma, PMA treatment only increased the level of the full-length, but not of the truncated, ICAM-1 mRNA. This shows that the PMA-responsive element is located within the 3'UTR. Furthermore, the effect of PMA on ICAM-1 delta 3 mRNA was recovered by ligating multiple AUUUA sequences derived from a heterologous gene fragment. The stability of this chimeric mRNA and the full-length ICAM-1 mRNA was markedly increased by PMA treatment, indicating that the AUUUA multimers in the 3'UTR are important in the PMA-induced upregulation of ICAM-1 mRNA. 相似文献
153.
Diaziquone given as a bolus has not been effective in patients with relapsed or refractory leukemia. Because of in vitro data suggesting enhancement of diaziquone-induced cytotoxicity for human and murine leukemia cells with increased duration of drug exposure and the relatively short terminal plasma half-life of diaziquone, 49 patients (34 acute nonlymphocytic leukemia [ANLL], six chronic myelogenous leukemia in blast crisis [CML-B], five acute lymphocytic leukemia [ALL], four 2 degrees ANLL) with leukemia were given diaziquone as a continuous infusion for seven days. The maximum tolerated dose was 28 mg/m2/d for seven days. The dose-limiting toxicity was the duration of bone marrow aplasia (median, 49 days to greater than 500 PMNs in responders; range, 28 to 101 days). Nonhematologic toxicity was minimal. Responses occurred only in patients with relapsed ANLL, of whom 26 were treated at effective doses. There were six complete responses (CR) (23%) and two partial responses (PR) (8%), although five of eight responders never achieved platelet counts greater than 100,000/microL. Thrombocytopenia in these patients was felt to be a manifestation of diaziquone effect, not persistence of leukemia. The median duration of CR was 195 days (range, 88 to 860+). One patient had active CNS leukemia at the start of treatment and has had a durable (28+ month) CR in both sites of disease. Diaziquone produced prolonged aplasia in patients with secondary ANLL and CML-B (five of ten patients died aplastic), whereas patients with ALL all had regrowth of leukemia and two failed to become aplastic. The lack of significant nonhematologic toxicity and the activity in patients with relapsed ANLL render diaziquone of interest as second-line therapy or consolidation therapy in first remission for patients with ANLL. 相似文献
154.
155.
156.
Alloimmunization is the major complication of platelet transfusion therapy in patients with acute leukemia. To evaluate whether alloimmunization continues to be a long-term problem in patients surviving induction therapy, 114 patients with acute nonlymphocytic leukemia (ANLL) who survived more than 6 mo and who received multiple courses of chemotherapy and abundant platelet transfusions were studied. Clinical response to random donor platelets and lymphocytotoxic antibody (LCTAb) were measured pretreatment and serially throughout the study period. Fourteen patients (12%) were alloimmunized upon admission, 34 (30%) patients became alloimmunized during remission induction therapy, and 66 (58%) patients did not become alloimmunized during that period. Sixty-one of these 66 patients (92%) never became alloimmunized and responded to random donor platelets during their subsequent course despite the fact they received multiple further platelet transfusions, whereas the alloimmunized patients tended to remain alloimmunized for their entire clinical course. There was no difference in age or sex between groups, and prognostic factors predicting alloimmunization could not be detected. In greater than 90% of patients not alloimmunized at admission, the presence or absence of LCTAb after induction predicts later alloantibody production. This information can be used to plan the type of platelet transfusions (HLA-matched or random donor) needed for subsequent maintenance and induction therapy. It may also help to identify a group of patients to whom more aggressive maintenance chemotherapy may be more safely administered. 相似文献
157.
Marleen Straat Marcella CA Müller Joost CM Meijers Mendi S Arbous Angelique ME Spoelstra - de Man Charlotte JP Beurskens Margreeth B Vroom Nicole P Juffermans 《Critical care (London, England)》2015,19(1)
IntroductionMuch controversy exists on the effect of a fresh frozen plasma (FFP) transfusion on systemic inflammation and endothelial damage. Adverse effects of FFP have been well described, including acute lung injury. However, it is also suggested that a higher amount of FFP decreases mortality in trauma patients requiring a massive transfusion. Furthermore, FFP has an endothelial stabilizing effect in experimental models. We investigated the effect of fresh frozen plasma transfusion on systemic inflammation and endothelial condition.MethodsA prospective predefined substudy of a randomized trial in coagulopathic non-bleeding critically ill patients receiving a prophylactic transfusion of FFP (12 ml/kg) prior to an invasive procedure. Levels of inflammatory cytokines and markers of endothelial condition were measured in paired samples of 33 patients before and after transfusion. The statistical tests used were paired t test or the Wilcoxon signed-rank test.ResultsAt baseline, systemic cytokine levels were mildly elevated in critically ill patients. FFP transfusion resulted in a decrease of levels of TNF-α (from 11.3 to 2.3 pg/ml, P = 0.01). Other cytokines were not affected. FFP also resulted in a decrease in systemic syndecan-1 levels (from 675 to 565 pg/ml, P = 0.01) and a decrease in factor VIII levels (from 246 to 246%, P <0.01), suggestive of an improved endothelial condition. This was associated with an increase in ADAMTS13 levels (from 24 to 32%, P <0.01) and a concomitant decrease in von Willebrand factor (vWF) levels (from 474 to 423%, P <0.01).ConclusionsA fixed dose of FFP transfusion in critically ill patients decreases syndecan-1 and factor VIII levels, suggesting a stabilized endothelial condition, possibly by increasing ADAMTS13, which is capable of cleaving vWF.
Trial registrations
Trialregister.nl NTR2262, registered 26 March 2010 and Clinicaltrials.gov , registered 14 June 2010. NCT01143909相似文献158.
Filipa Morais-Santos Sara Granja Vera Miranda-Gon?alves António H.J. Moreira Sandro Queirós Jo?o L. Vila?a Fernando C. Schmitt Adhemar Longatto-Filho Joana Paredes Fátima Baltazar Céline Pinheiro 《Oncotarget》2015,6(22):19177-19189
Background
Most cancers, including breast cancer, have high rates of glucose consumption, associated with lactate production, a process referred as “Warburg effect”. Acidification of the tumour microenvironment by lactate extrusion, performed by lactate transporters (MCTs), is associated with higher cell proliferation, migration, invasion, angiogenesis and increased cell survival. Previously, we have described MCT1 up-regulation in breast carcinoma samples and demonstrated the importance of in vitro MCT inhibition. In this study, we performed siRNA knockdown of MCT1 and MCT4 in basal-like breast cancer cells in both normoxia and hypoxia conditions to validate the potential of lactate transport inhibition in breast cancer treatment.Results
The effect of MCT knockdown was evaluated on lactate efflux, proliferation, cell biomass, migration and invasion and induction of tumour xenografts in nude mice. MCT knockdown led to a decrease in in vitro tumour cell aggressiveness, with decreased lactate transport, cell proliferation, migration and invasion and, importantly, to an inhibition of in vivo tumour formation and growth.Conclusions
This work supports MCTs as promising targets in cancer therapy, demonstrates the contribution of MCTs to cancer cell aggressiveness and, more importantly, shows, for the first time, the disruption of in vivo breast tumour growth by targeting lactate transport. 相似文献159.
目的 探讨热休克蛋白72肽结合区在肾小管上皮间质转分化(EMT)过程中的作用和可能机制.方法 应用质粒转染方法分别诱导热休克蛋白72(HSP72)野生型、肽结合区缺失型(HSP72-△PBD)和肽结合区(PBD)的表达.用转化生长因子β1(TGF-β1)刺激大鼠肾小管上皮细胞(NRK-52E)48 h,Western印迹和免疫荧光染色检测细胞E-钙黏蛋白(cadherin),α-平滑肌肌动蛋白(SMA),HSP72和Smad3/磷酸化(p)-Smad3蛋白表达.结果 TGF-β1(10 μg/L)刺激NRK-52E细胞48 h后上调α-SMA和下调E-cadherin蛋白表达水平.Western印迹及细胞免疫荧光显示,过表达HSP72和PBD能明显减轻TGF-β1诱导的NRK-52E细胞E-cadherin蛋白表达下调和α-SMA蛋白表达上调,而过表达HSP72-△PBD不能改变上述蛋白的表达.此外,过表达HSP72和PBD显著抑制Smad3的磷酸化.结论 HSP72抑制Smad3活化和EMT的发生可能与PBD的功能有关. 相似文献
160.
Marcella CA Müller Kirsten Balvers Jan M Binnekade Nicola Curry Simon Stanworth Christine Gaarder Knut M Kolstadbraaten Claire Rourke Karim Brohi J Carel Goslings Nicole P Juffermans 《Critical care (London, England)》2014,18(6)